KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Ionis Pharmaceuticals (IONS) Accumulated Depreciation & Amortization (2016 - 2025)

Ionis Pharmaceuticals (IONS) has disclosed Accumulated Depreciation & Amortization for 12 consecutive years, with $109.1 million as the latest value for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 11.59% year-over-year to $109.1 million; the TTM value through Dec 2025 reached $109.1 million, up 11.59%, while the annual FY2025 figure was $109.1 million, 11.59% up from the prior year.
  • Accumulated Depreciation & Amortization hit $109.1 million in Q4 2025 for Ionis Pharmaceuticals, up from $97.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $109.1 million in Q4 2025 and bottomed at -$105.3 million in Q4 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $38.0 million, with a median of $88.2 million recorded in 2023.
  • Year-over-year, Accumulated Depreciation & Amortization surged 154619.3% in 2023 and then grew 10.84% in 2024.
  • Ionis Pharmaceuticals' Accumulated Depreciation & Amortization stood at -$105.3 million in 2021, then soared by 100.05% to $57000.0 in 2022, then soared by 154619.3% to $88.2 million in 2023, then rose by 10.84% to $97.7 million in 2024, then rose by 11.59% to $109.1 million in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $109.1 million, $97.7 million, and $88.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.